NCT00367445已完成4 期
A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Variability of blood glucose over a period of 72 hours
研究概览
简要总结
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetes mellitus Type 2
排除标准
- •Severe Asthma, severe COPD
结局指标
主要结局
Variability of blood glucose over a period of 72 hours
次要结局
- Insulin pharmacokinetics
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®Diabetes Mellitus, Type 2NCT00391027Pfizer261
终止
4 期
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®Diabetes Mellitus, Type 1NCT00356421Pfizer58
已完成
3 期
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 DiabetesDiabetes MellitusNCT00348374Pfizer191
已完成
3 期
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 YearsType 2 DiabetesNCT02725593AstraZeneca72
已完成
3 期
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.Diabetes Mellitus, Type 2NCT00370565Pfizer345